跳至主要内容
临床试验/NCT02276170
NCT02276170终止不适用

Pharmacology of Aminophylline for Acute Kidney Injury in Neonates

Stanford University1 个研究点 分布在 1 个国家目标入组 9 人开始时间: 2014年10月最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
9
试验地点
1
主要终点
Drug concentrations of theophylline

研究概览

简要总结

Acute kidney injury (AKI) in critically ill neonates is common and associated with significant morbidity and mortality. No targeted therapeutic treatment strategies have been established for AKI in neonates. Within a clinical pharmacokinetic and pharmacodynamic conceptual framework, this project will examine the medication aminophylline as a potential treatment approach for AKI.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
— 至 3 Months(Child)
性别
All
接受健康志愿者

入选标准

  • Neonate < 3 months post natal age
  • Diagnosed with acute kidney injury (AKI)
  • Receiving aminophylline for AKI treatment as per local standard of care.

排除标准

  • Presence of anatomical renal anomaly based on postnatal evaluation of the patient (hydronephrosis, multicystic kidney, renal agenesis, renal dysplasia, polycystic kidney, or obstructive uropathy)
  • Patient on renal replacement therapy
  • Major genetic abnormalities (trisomy 13, 18 or 21).

结局指标

主要结局

Drug concentrations of theophylline

时间窗: Day 1 or 2 and Day 3,4, or 5

次要结局

  • Change in serum creatinine level(Day 1,2,3,4,5)
  • Number of participants with adverse events(5 days)
  • Change in urine biomarker levels(Day 1,2,3,4,5)
  • Change in renal Near-infrared spectroscopy (NIRS)(Day 1,2,3,4)
  • Change in urine output(Day 1,2,3,4)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Adam R Frymoyer

Clinical Assistant Professor

Stanford University

研究点 (1)

Loading locations...

相似试验